Ironwood Pharmaceuticals Inc (IRWD) stock
IRWDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3062% below fair value
$4.78−0.09 (-1.85%)
Close on Nov 18, 2026Market cap $789.85MP/E 6.2Yield –
Ironwood Pharmaceuticals pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Ironwood Pharmaceuticals's pe ratio was 6.2× on Nov 10, 2026, against 23.3× a year earlier. Over the last 5 years it ranged from 3.4× to 161.0×, with a median of 13.0×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 10, 2026 | 6.2× | −16.2 |
| 2025 | Dec 31, 2025 | 22.5× | −76.3 |
| 2024 | Oct 31, 2024 | 98.8× | +87.8 |
| 2023 | Jul 31, 2023 | 11.0× | −2.1 |
| 2022 | Dec 30, 2022 | 13.0× | +9.5 |
| 2021 | Dec 31, 2021 | 3.6× | −12.9 |
| 2020 | Dec 31, 2020 | 16.5× | – |
See a number that looks wrong?